Treatment for osteoporosis using growth hormone releasing factor

Details Treatment for osteoporosis using growth hormone releasing factor Treatment for osteoporosis using growth hormone releasing factor

1991-11-04

1992-11-17

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 2, 514 21, A61K 3736

Patent

active

051643685

ABSTRACT:
A method of treating osteoporosis, especially postmenopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)-NH.sub.2, or a biologically active analog thereof, and concurrently administering parathyroid hormone, PTH(1-34)-NH.sub.2 and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.

REFERENCES:
patent: 4710382 (1987-12-01), Recker
patent: 4870054 (1989-09-01), Recker
Reeve et al, Osteoporosis Int (1991), 162-170.
Neer et al. Osteoporosis (1987), 829-835.
Reeve et al. Br. med. J. (1980), 280-1340-4.

Affiliated with

Also associated with

Rating

Treatment for osteoporosis using growth hormone releasing factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment for osteoporosis using growth hormone releasing factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for osteoporosis using growth hormone releasing factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1172112